unique electron paramagnetic resonance (EPR) spectrum1^contains iron as Fe(III)8) and at least one atom of oxygen originally derived from O21}. Activated bleomycin is formally an Fe(V) complex which requires two reducing equivalents to be discharged to the catalytically inactive species, Fe(III)-bleomycin9). In this way, the redox properties of activated bleomycin resemble activated complexes of various peroxidases and the putative activated form of cytochrome P-45010'n).
In the presence of DNA,activated bleomycin initiates a series of reactions leading to the formation of specific DNAbreakdown products12). In air, base propenal formation12~14), stoichiometric with15) and subsequent to16) DNAstrand scission, occurs. Concomitant with attack on DNA,activated bleomycin is reduced to Fe(III)-bleomycin, with the rate of reduction equal to the rate of oxidative lesion formation in DNA1}. Subsequent addition of Fe(II)17) or reduction of Fe(III) in situ18>1Q:> leads to the reactivation of the drug, which is capable of continuing DNAbreakdown to a point which is believed to be limited by the ability of the drug to bind to DNA5).
If, however, DNAis not present, activated bleomycin undergoes a self-inactivation process such that the ability of the drug to cleave DNAis not fully restored upon subsequent addition of Fe(II) and O21}. The rate of self-inactivation is the same as the rate of attack on DNA,if present, and is concomitant with the formation of a species with the same optical and EPRproperties as Fe(III)-bleomycin.
In this communication, we describe the conversion of bleomycin A2, one of the isomers found in the commercial preparation Blenoxane, into a product that retains the ability to generate the species formed with Fe(II) and O2 having the EPR properties of activated bleomycin, and yet is incapable of cleaving DNA.The inactive form exhibits altered fluorescence properties compared to bleomycin A2 which indicate an alteration of the bithiazole residue. It is suggested that the alteration or destruction of the bithiazole residue reduces binding to DNAand this is largely responsible for the loss of DNAcleavage activity.
Materials and Methods Materials
Bleomycin sulfate (Blenoxaneá") was a gift from Bristol Drugs. Calf thymus DNAwas obtained from Sigma and was dissolved in 20 mMsodium phosphate, pH 7.0. The concentration was calculated on the basis of E260 6.6 (mMnucleotide)"1 cm"1. Analytical grade ferric and ferrous ammonium sulfate (Baker) were dissolved in distilled water before use. All reactions were carried out at room temperature, unless otherwise noted, in 20 mMsodium phosphate buffer, pH 7.0.
Purification of Bleomycin A2 Bleomycin A2 was purified from Blenoxane. Chelex-treated, distilled, and deionized water was used throughout the purification.
The drug (80 mg) was dissolved in 3 ml H2Oand was applied to a 14x400 mmCM-Sephadex C-25 columnf equilibrated with 50 mMammonium formate, pH 6.5. After washing the column with 200 ml of the same buffer, the various bleomycin isomers were eluted by linear gradient up to 1.0 m ammoniumformate, pH 6.5, monitoring column eluates at 254 nm. Peak fractions were combined, lyophylized, and minimal amounts of water were added to dissolve crystalline salts and drug. Desalting was carried out on a 14x400-mmSephadex G-10 column, monitoring bleomycin elution visually from its light yellow color. The identity as well as the purity of the isolated bleomycins was based on chromatographic elution profiles and by TLC on pre-coated Silica gel 60 F254 plates from EMLaboratories, according to the method of Roy et al. Preparation of Bleomycin A2 Oxidation Product ; Eight 20-[A aliquots of 20 mMFe(II) were added sequentially to 2 ml of a gently stirred solution of 0.2 mMbleomycin A2, with 15 minutes incubations between additions. The product and untreated bleomycin A2 were separated on Silica gel 60 TLC plates (20 x 20 cm) from EMLaboratories, developed in methanol -10% (w/v) ammoniumacetate (10 : 9) . In this solvent the Rf of bleomycin A2 was 0.41. The product band (Rf 0.35) showed a yellow fluorescence as compared to a blue fluorescence for the parent compound, and was scraped from the plate. The product was eluted from the silica gel with 10 mMHC1and, after centrifugation, the supernatant was neutralized with 0.1 mNaOH.This solution was used for optical spectral and fluorescence studies.
Assay of Bleomycin Activity Bleomycin activity was judged from the yield of base propenal which results from DNAbreakage when Fe(II) is added aerobically. Base propenal was assayed by the thiobarbituric acid procedure described previously12). The reaction mixture contained 0.08 mMbleomycin A2, 0.5 mMDNAand 0.08 mMFe(II). Aliquots (0.4 ml) were added to 0.6 ml of 40 im 2-thiobarbituric acid containing 1 mMEDTA.Mixtures were heated at 100°C for 15 minutes and subsequently cooled to room temperature. The adduct formed with 2-thiobarbituric acid was quantitated based on the extinction coefficient at 532 nm (EmM 160 cm"1)1^.
Fluorescence Studies
A Perkin-Elmer fluorometer, Model MPF-3, was used for fluorescence and kinetic measurements22>23). Titration of bleomycin A2 with Fe(II) was carried out under anaerobic conditions in a quartz Thunberg fluorescence cell fitted with rubber septum stoppers. The cell, containing 0.02 mM bleomycin A2 in 20 mMphosphate buffer (pH 7.0) in the central cuvette and Fe(II) in the side arm, was thoroughly degassed with highly purified argon. The fluorescence was measured before and after mixing with Fe(II) and after subsequent mixing of the solution with air. Fluorometric studies of Cu(II), Fe(III) and Zn(II) binding were carried out aerobically. Bleomycin solutions were titrated with metal ion and the fluorescence was recorded 10 minutes after additions, the time needed in some cases to achieve equilibrium.
EPR Spectroscopy
Activated bleomycin (g=2.26, 2.17, 1.94) and Fe(III>bleomycin (#=2.45, 2.18, 1.89) were identified using EPR spectroscopy1 '17) . Activation of the bleomycin A2 oxidation product was carried out as follows: Ten individual 10-/4 aliquots of 50 mMFe(II) were added to a 1-ml stirred solution containing 0.5 mMbleomycin A2 in 20 mMphosphate buffer, pH 7.0, with 15 minutes incubation between each addition. After the final addition and incubation, the solution was centrifuged for 10 minutes to remove iron precipitates. Subsequent steps were carried out at 0°C. A 10-/4 aliquot of 50 mM Fe(II) was added to the supernatant to re-initiate the activation reaction1}. A200-/4 aliquot was diluted with 200 /d ethylene glycol, required for the formation of a glass for low temperature EPR study, and the sample was quickly transferred to an EPRtube and frozen in liquid N2 (~40 seconds). As a control, Fe(II) was added to untreated bleomycin A2 which was diluted as above and frozen for EPR examination.
The EPRspectrum of the Cu(II) complex of bleomycin A2 and the catalytically inactive oxidation product were obtained by the addition of 0.4 mMCu(II) instead of Fe(II) to a bleomycin solution originally in 20 mMHEPES, pH 7.3. Spectra were recorded as described previously1}.
Results
The fluorescence of bleomycin A2 with an emission maximumat 353 nm (excitation at 300 nm), is assigned to the 2,4-bithiazole group23). Fig. 1 shows the fluorescence properties of the drug when it is titrated with different transition metal ions. Under metal ion saturating conditions, the fluorescence quenching order is Cu(II) » Fe(II)>Zn(II). Tight metal binding20 is confirmed by the sharp breaks in the titration curves and the extinction coefficient for the drug21) is verified. The result of a titration with Fe(III) is shown in Fig. IB and it is evident from the shape of the curve that it binds far weaker to the drug than the other metal ions. A log plot of the binding data is shown as an insert to Fig. IB . The association constant for Fe(III), 3.2xlO4, is smaller by three orders of magnitude than for Fe(II), 2.7 X lO7 24), and supports the view that Fe(II) can replace bleomycinbound Fe(III).
When a 2-fold molar excess of Fe(II) is added anaerobically to bleomycin A2, the fluorescence is partially quenched (Fig. 2A, curve b) . Whenthis solution is aerated, a further change in fluorescence is observed (Fig. 2A, curve d) . The fluorescence yield of this product is less than that of an untreated bleomycin A2 solution to which a 2-fold molar excess of Fe(III) was added ( Fig. 2A, curve c) , suggesting that an alteration of the fluorophore had taken place. In a separate study (Fig. 2B) , the time course of alteration of fluorescence brought about by the aerobic addition of five aliquots of 20^m Fe(II) is compared to a single addition of 100^m Fe(II) to a solution of 20^m bleomycin. The fluorescence yield at the end of five additions does not differ significantly from that where a single addition of 100^m Fe(II) is made, but it is less than that observed when 100 [im Fe(III) is added de novo to bleomycin A2 (Fig, IB) . The total change in fluorescence in each step is complete in about 2 minutes (if oxygen levels are reduced, the time course for the fluorescence change after a single addition of Fe(II) can be prolonged to as much as 15 minutes). It is suggested from these studies that the Fe(II) binding reaction, activation with O2, and displacement of Fe(III) formed from activated bleomycin is completed within 2 minutes at room temperature. When Fe(II) is added to bleomycin A2 in air, partial self-inactivation of the drug occurs when DNAis absent1»12) and a loss of DNAcleaving activity can be demonstrated when DNAis added after re-addition of Fe(II) to a partially inactivated sample. Data from such a study is shown in Fig.  3 where Fe(II), equimolar with bleomycin, is allowed to react aerobically with the drug. A subsequent . Data were normalized to 100%for the untreated drug. It should be noted that soon after the introduction of Fe(II), at least after the first introduction, the fluorescence decreases to a minimumto which it rises to a higher value at equilibrium. It is possible that a short lived intermediate is formed having fluorescence properties different from that of more stable reaction products. addition of Fe(II) is made, and the catalytic activity is measured as base propenal release from added DNA12). Each subsequent addition of Fe(II) up to a total of 6 equivalents causes roughly a 14%-loss of DNAcleaving activity. After 10 additions of Fe(II), only 6% of the original activity remains.
Concomitant with the loss of ability of bleomycin A2 to cleave DNA,there is a conversion of the drug to a product with a decreased Rf on TLC. This conversion which occurs in aerobic reactions with Fe(II) is prevented when DNAis present (data not shown). Each addition of Fe(II) causes a loss of bleomycin A2 with the appearance of a product that does not migrate in methanol -10% ammonium acetate (w/v) -10% ammonium hydroxide (10 : 9 : 1), (the Rf for bleomycin A2 here is 0.37). In methanol -10% (w/v) ammoniumacetate (10 : 9) the product migrates with an Rf of 0.36 while bleomycin A2 has an Rf of 0.47 in this system.
In Fig. 4A , we compare the optical spectra of bleomycin A2 and the inactivated product recovered after TLC (Fig. 4B) arbitrarily adjusting the absorption of the latter at 290 nm to be similar to that of untreated bleomycin A2. Although the shoulder near 245 nm is the same for both samples, the absorption near 290 nmfor the product is broadened. Also, the ability of inactivated bleomycin to release base propenal from DNAwith Fe(II) is only 7 % that observed for bleomycin A2, for solutions having comparable absorptions at 290 nm. Fig. 4C is the fluorescence emission spectrum of the bleomycin A2 solution, whose optical spectrum is given in Fig. 4A , taken with an excitation wavelength of 300 nm. The fluorescence maximumis at 353 nm. Whenthe fluorescence spectrum of the inactivated product whose spectrum is given in Fig. 4B is examined, an emission is also observed at 353 nm, but with only 10% of the fluorescence intensity of that in Fig. 4C . Excitation at 394 nm, though, produces the fluorescence emission shown in Fig. 4D . When DNAis added to bleomycin A2, the fluorescence of the drug (Fig.   4C ) is partially quenched, which indicates that binding to DNAoccurs22»23). With the inactive product (Fig. 4D ), no such quenching by DNA is seen.
In Fig. 5A , we compare the EPRspectrum of the Cu(II) adduct of the inactivated product with that of Cu(II)-bleomycin A2. It can be readily seen that the spectra are identical, suggesting that the equatorial ligands to Cu(II)24~26) are the same in both complexes. When Fe(II) is added to the inactivated product at 0°C, the resulting EPR spectral lineshape (Fig. 5B ) is identical to that seen when Fe(II) is added to bleomycin A2 never treated with Fe(II). This suggests that even though the inactivated drug has a markedly reduced DNAcleavage activity, it retains its ability to activate oxygen in the same way as the active drug. 
Discussion
In the absence of DNA,activated bleomycin, formed from the autoxidation of O^FeCII^bleomycin1'70, is partially self-inactivated. Subsequent addition of DNAand re-addition of Fe(II) yields less DNAcleavage products compared to the yield from activated drug not initially cycled with Fe(II). Other studies have shown that base propenal release accompanying DNAcleavage15) requires O2 subsequent to drug activation, either with Fe(II) and O2 or with Fe(III) and peroxide1}. In contrast, partial inactivation of the drug does not require O2 beyond that necessary for activation of Fe(II)-bleomycin27).
In this way, drug self-inactivation mayresemble a reaction of activated bleomycin with DNAthat takes place when O2 is limited12>u>28\
Early studies addressed to drug self-inactivation by treatment with Fe(II) suggest that there is the release of a fragment from the molecule3) while a change in the 13C NMR spectrum also suggested an alteration in the pyrimidine structure29).
Gutteridge and Shute30) suggest that the polarity of bleomycin is altered when it is self-inactivated, and this is borne out from the changes in Rf we observe for the product. Evidence from spectroscopic data and chromatographic behavior suggest that the structure of bleomycin is altered when it is inactivated, though no alteration in metal binding properties can be demonstrated. Fe(III)-bleomycin generated from Fe(II)-bleomycin is reported to have the same pK%determined by optical titration, as the complex formed by de novo addition of Fe(III) to the drug17) suggesting that no alteration in ionizable groups associated with metal binding occur. Further, the EPR of the Cu(II) complex of inactivated drug, indicates identical metal coordination (Fig. 5) . A major difference, however, is observed in the optical and fluorescence properties of the mole- Trace (A) is the UVspectrum of 20 im bleomycin A2 and trace (B) of the oxidation product formed by aerobic addition of Fe(II) and separation by TLC. The absorption at 290 nm of the solution in (B) was arbitrarily adjusted to be similar to that in (A). Measurements were carried out in 10 mMphosphate buffer, pH 7. Trace (C) is the fluorescence spectrum studied with an excitation wavelength of 300 nm of the bleomyein A2 solution whose optical spectrum is given in trace (A). (D) is the fluorescence spectrum of the product having the optical spectrum shownin trace (B) using an excitation wavelength of 394 nm. In (C) and (D), the effects of DNAaddition (concentrations are given in the figure) on the fluorescence properties of bleomycin A2 and of the oxidation product are indicated.
cule when it becomes inactivated. Notable in these is a broadening of the 290 nm absorption band (Figs. 4A and 4B ) and the diminution of the fluorescence emission near 350 nm as well as the formation of a new fluorescent species (Fig. 4D) . In addition to spectral and fluorescence change, the ability of the bleomycin molecule to release base propenal from DNAwhen Fe(II) is added is impaired (Fig. 3) .
This result is to be compared with the recent report by Morii et alzl\ of a photo-transformed Cu(II)-bleomycin that exhibits a broadened optical absorption near 290 nm, similar to the one we observe for Fe(II)-inactivated bleomycin. The fluorescence emission maximumfor the photo-transformed product is shifted to 410. In this, as well as in our own study, an alteration in bithiazole Upper traces : Trace (A) is the EPR spectrum of the Cu(II) complex formed with the inactive product formed by multiple additions of Fe(II) to bleomycin A2. Trace (B) is the spectrum of Cu(II) with authentic bleomycin A2.
Lower traces: A similar comparison of spectra of product formed subsequent to Fe(II) addition to Fe(II)-inactivated bleomycin A2 (C) and authentic bleomycin A2 (D). Samples were diluted 1 : 1 with ethylene glycol. A control sample of activated bleomycin A2 was prepared by adding Fe(II) to an aerobic drug solution that had never been pretreated with Fe(II), diluting with ethylene glycol and freezing for EPRexamination. Spectra were recorded at 77 K on a Varian E-12 spectrometer as described previously170 with a microwave power of 10 mWand a modulation amplitude of 20 G. The g values are indicated in the figure. structure is suggested. Unlike the self-inactivated product reported here, there is no report of reduction of DNAcleavage activity of the photo-transformed product.
In summary, we describe the preparation of an inactivated product of bleomycin with a markedly reduced catalytic potential for base propenal release from DNAwith Fe(II) and O2. An EPR study shows that Cu(II) ligation to the inactivated drug is unchanged and, further, that a paramagnetic species can be produced from Fe(II) and O2 having the same EPR spectrum as activated bleomycin (Fig. 4) , a molecule shown to contain Fe(III) and at least a single atom of oxygen derived from O21'8). It is suggested that reduction of catalytic activity is a consequence of alteration of bithiazole structure involved in the binding of the drug to DNA32).
